profile picture of Matthew A. Chivvis

Matthew A. Chivvis

Partner | San Francisco

The ability to immerse yourself in the science of your clients’ innovations is non-negotiable.


Obtained a complete win for Seagen of willful infringement, no invalidity, and all requested damages in a jury trial involving antibody-drug conjugate technology.

Lead counsel for the University of California and Evolve BioSystems in a patent case involving probiotic supplements for use with preterm infants.

Lead counsel for Driscoll’s in a dispute regarding strawberry breeding and plant patent rights.

Lead counsel for Bayer in trade secret misappropriation case involving biofungicide products. Case settled on favorable terms.

Trial counsel for the University of California in a dispute regarding strawberry breeding and plant patent rights. Obtained a jury verdict in client’s favor of conversion and patent infringement by defendants.

Represented Genentech in district court and inter partes review proceedings involving patent directed to tyrosine kinase inhibitor combination therapies. Board determination in Genentech’s favor was affirmed on appeal.

Obtained summary judgment of non-infringement for Genentech in a case involving a patent directed to breast cancer treatments and a $1.7 million fee award. Affirmed on appeal.

Defended the validity of patents protecting one of Genentech’s blockbuster breast cancer therapeutics. Board declined to grant review on one patent after a preliminary response was filed. Board later issued a Final Written Decision rejecting the petitioner’s grounds for unpatentability on the other patent. Phigenix’s appeal to the Federal Circuit was dismissed for lack of standing.

Represented Focal in review of patented methods relating to the treatment of breast cancer. Case settled on favorable terms.

Ranked in California for Litigation

IAM Patent 1000 2022-2023

Winner: Top 100 Verdicts

The National Law Journal 2022